Big Cypress Acquisition scheduled an Oct. 20 meeting for shareholders to vote on the proposed merge with SAB Biotherapeutics. The S-4 registration statement on the deal has been decalred effective by the SEC.
The proposed transaction implies an enterprise value for SAB, on a post-merger basis, of approximately $325 million and is expected to provide the combined company with approximately $118 million of pro forma cash (assuming no redemptions from Big Cypress’ trust account).
SAB is a clinical-stage biopharmaceutical company developing a novel immunotherapy platform producing targeted, high potency, fully-human polyclonal antibody therapeutics and advancing programs in infectious disease, immune system disorders and oncology.
If approved, upon closing SAB Biotherapeutics’ common stock and warrants will list on the Nasdaq under DIVR and DIVRW. Read more.
